ASDERA develops interventions for unmet needs by utilizing a patented computational biostatistics platform to identify complex genetic risk factors in small (from n?500) epidemiological and 'failed' phase 2/3 studies.
The ASDERA time-/pipeline:
- Validation: Confirmation of known drug targets in epilepsy
(2013, Pharmacogenomics) - Proof-of-principle: L-fucose in Crohn's disease
(in progress, from 2006 dbGaP data) - Autism: A derivative of mefenamic acid against mutism in autism (2014, Nature: Transl. Psychiatry, $500M valuation)
- Lysosome function treatments: Intestinally absorbed derivatives of HP-a-cyclodextrin (pat. pending) against progression of
- carcinomas (breast cancer, https://doi.org/10.1371/journal.pone.0199012 ) - - neurodegeneration (Alzheimer's, Parkinson's, Huntington's, ALS)
- - lysosomal storage diseases (NPC, TS, Fabry, Sandhoff, Farber, ...)
- Nutritional products: Novel formulation of a-cyclodextrin (pat. granted) for use in dietary supplements and food as
- 'fasting mimetic' to improve the natural process of aging - - 'adaptive vaccination' to reduce severity of initial infection with
SARS-CoV-2 while developing COVID-19 immunity.
